Endocrine Abstracts

Contents

• 18th Annual Meeting of the UK and Ireland Neuroendocrine Tumour Society 2020
• • Oral Communications
  • • Identification of soluble immune checkpoint receptor landscape in liver metastases of neuroendocrine neoplasms: A new perspective for immunotherapy

      ea0072oc1
    • COVID19 & My Care: NCUK community experience

      ea0072oc2
    • OMIC gene cluster evaluation amplifies the prognostic accuracy of the NETest

      ea0072oc3
• Poster Presentations
• • (1)
  • • Post-operative NETest scores detect residual NET disease and accurately predicts tumor recurrence in R0

      ea0072p1
    • Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients (SCAN) - UK and Ireland vs global diagnosis of NETs

      ea0072p2
    • Circulating biomarkers to predict progression-free survival in patients with neuroendocrine tumours received ¹⁷⁷Lu-DOTATATE

      ea0072p3
    • Telotristat in the management of Carcinoid diarrhoea - real world experience of patients from an ENETs centre of excellence in Neuroendocrine tumours.

      ea0072p4
    • Allelic deletion of chromosome 18 is common in intra-abdominal neuroendocrine neoplasms

      ea0072p5
    • Metachronous neuroendocrine neoplasms in England 2013-2015

      ea0072p6
    • Carcinoid heart surgery: Review of outcomes from a single large centre

      ea0072p7
    • The prevalence of depression and anxiety among neuroendocrine tumour and general gastroenterology outpatients and the psychometric validity of emotional thermometers

      ea0072p8
    • Zoom-ing in on natters: Neuroendocrine cancer UK (NCUK) patient support groups during COVID pandemic

      ea0072p9
    • Are outcomes of patients with advanced well-differentiated GEP-NETs on somatostatin analogues similar, irrespective of tracer uptake on ⁶⁸gallium DOTA SSTR peptide PET CT scans?

      ea0072p10
    • The discontinuation of interferon-alfa for the treatment of metastatic NET: A case amongst many of poorer patient outcomes?

      ea0072p11
    • A new diagnosis of both a pituitary TSH-oma and a metastaticneuroendocrine tumour

      ea0072p12
    • Well-differentiated Gastroenteropancreatic G3 NET: Findings from a large single centre cohort

      ea0072p13
    • Effective multimodality therapy for a metastatic insulin-secreting pancreatic neuroendocrine tumour (NET): A case report

      ea0072p14
    • Specialist dietetic input in the south wales NET clinic: Patient outcomes

      ea0072p15
    • Mixed neuroendocrine-non-endocrine neoplasms (MiNEN): A case of pancreatic acinar - neuroendocrine carcinoma of large cell type

      ea0072p16